$COLL

Collegium Pharmaceutical shares fell about 13% in pre-open trading after it reported Q2 2026 results and cut full-year revenue guidance. Net revenues were $199.9M, up 6.3% but below analysts’ ~$201.2M-$201.4M. Adjusted EPS was $1.92 and adjusted EBITDA $113.8M. The pain portfolio faced generic competition, while JORNAY PM rose 41% to $46.1M and AZSTARYS added $12.9M.

Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 CY2026 revenue of $199.9 million, up 6.3% year on year but below analyst estimates. Full-year revenue guidance of $840 million midpoint was 3.4% under consensus. Non-GAAP EPS was $1.92, up from $1.68 and 8.8% above estimates. The stock fell 6.6% to $33.37.

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 coll-2026x06x30xex99x1.htm EX-99.1 Document Exhibit 99.1 Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress – Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Gener

Collegium Pharmaceutical (COLL) will report earnings Thursday before market open. The company previously posted $193.5M revenue, up 8.9% year over year, and beat EPS estimates but missed full-year revenue guidance. For the upcoming quarter, analysts expect revenue growth of about 7% y/y. COLL shares are below its average $53.60 analyst price target.

Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 2026 results on May 7, with revenue up 9% YoY to $193.5 million, beating the Street’s $187.4 million estimate. Adjusted EPS rose to $1.76 from $1.49 and topped expectations of $1.63. The company cited strong ADHD franchise growth, including Jornay PM sales up 36% YoY, and expects Jornay PM revenue of $190–$200 million in 2026. Collegium also plans to expand its ADHD portfolio via Azstarys acquisition, expecting it to add over $50 million to H2 2

Collegium Pharmaceutical (COLL) director Donovan Michael Glancy has filed an initial Form 3, indicating his start as a reporting person for the company. This filing discloses his initial ownership of Collegium Pharmaceutical securities but does not report any transactions or derivative positions. A Form 3 is a mandatory SEC filing for new insiders, establishing a baseline for their holdings.

COLLEGIUM PHARMACEUTICAL, INC. director Carlos V. Paya was granted 8,741 restricted stock units (RSUs) as compensation, increasing his direct holdings to 28,323 shares. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, contingent on his continued board service. The grant price was $0.00, and the settlement will be in common stock shares upon vesting or under specific conditions like the end of his board service or a change in control.

Collegium director Rita J. Balice-Gordon was granted 8,741 Restricted Stock Units (RSUs), increasing her direct holdings to 61,370 shares. These RSUs vest on the earlier of May 14, 2027, or the company’s 2027 Annual Meeting of Shareholders, provided she continues her service as a director. The grant, detailed in a Form 4 filing, is a form of equity compensation.

Collegium Pharmaceutical director Gino Santini was granted 8,741 restricted stock units (RSUs) on May 14, 2026, as an equity award with a $0.00 purchase price. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, provided he continues his service as a director. Following this grant, Santini directly holds 103,783 shares of Collegium common stock, illustrating a form of compensation tied to continued service and company performance.

Collegium Pharmaceutical director John Gordon Freund recently sold 4,127 shares of common stock, exercised options for 8,700 shares, and received a grant of 8,741 restricted stock units (RSUs). After these transactions, his direct holdings stand at 83,972 shares, with additional indirect holdings through family partnerships and investment firms. The RSUs are set to vest by May 14, 2027, or the company's 2027 annual meeting, contingent on his continued board service.